Tag Archives: TXMD

Noble Financial Sticks to Its Buy Rating for TherapeuticsMD (TXMD)

Noble Financial analyst Ahu Demir maintained a Buy rating on TherapeuticsMD (TXMD – Research Report) yesterday. The company’s shares closed last Monday at $3.78. According to TipRanks.com, Demir is a 3-star analyst with an average return of 5.8% and a

TherapeuticsMD (TXMD) Receives a Buy from Noble Financial

In a report issued on August 9, Ahu Demir from Noble Financial maintained a Buy rating on TherapeuticsMD (TXMD – Research Report), with a price target of $13. The company’s shares closed on Friday at $3.10. According to TipRanks.com, Demir

A Director at TherapeuticsMD (NASDAQ: TXMD) is Buying Shares

Today, a Director at TherapeuticsMD (TXMD – Research Report), Cooper Collins, bought shares of TXMD for $99.6K. This recent transaction increases Cooper Collins’ holding in the company by 83.33% to a total of $218.5K. In addition to Cooper Collins, one

Oppenheimer Sticks to Their Buy Rating for TherapeuticsMD (TXMD)

Oppenheimer analyst Jay Olson reiterated a Buy rating on TherapeuticsMD (TXMD – Research Report) today and set a price target of $14. The company’s shares closed yesterday at $5.09. Olson noted: “TXMD reported 4Q results and launch progress for 2019

Oppenheimer Reaffirms Their Buy Rating on TherapeuticsMD (TXMD)

Oppenheimer analyst Jay Olson maintained a Buy rating on TherapeuticsMD (TXMD – Research Report) yesterday and set a price target of $14. The company’s shares closed on Friday at $5.23. Olson observed: “TXMD provided an update on the Imvexxy launch

TherapeuticsMD (TXMD) Gets a Buy Rating from Oppenheimer

Oppenheimer analyst Jay Olson maintained a Buy rating on TherapeuticsMD (TXMD – Research Report) yesterday and set a price target of $14. The company’s shares closed yesterday at $5.10. Olson said: “We met management for an update on Imvexxy launch